Preclinical Pipeline

Addex has built a pipeline of programs from early Hit-to-Lead to late lead optimization and clinical candidate selection. All our programs are based on allosteric modulation, either positive or negative, and represent unique opportunities for development of novel therapies for diseases with high unmet medical need. We are actively advancing these programs through their respective stages to deliver first-in-class small molecules for diseases with high unmet medical need. All our programs benefit from high-level collaborations with leading academic labs, as well as the funding support from: industrial partners such as Indivior plc and Janssen Pharmaceuticals; governmental agencies such as InnoSuisse and NIDA; and patient advocacy groups such as The Michael J Fox Foundation.

Extensive Discovery Stage Pipeline Driving Long-Term Growth.jpg